Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Icatibant for patients with type III hereditary angioedema: a review of clinical effectiveness and harms. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2014 Authors' conclusions One small observational study showed that icatibant appeared effective and safe in the treatment of type III HAE acute attack. However, it is inconclusive and needs to be interpreted with caution due to the important methodological limitations of the body evidence. No evidence for the prophylactic effectiveness of icatibant for patients with type III HAE was found. No evidence on harms associated with long-term use of icatibant is found. Better designed RCTs or larger scale observational studies in Canadian settings are needed to further determine the therapeutic or prophylactic effectiveness and harms of icatibant for patients with type III HAE. Indexing Status Subject indexing assigned by CRD MeSH Bradykinin; Hereditary Angioedema Type IIIs Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000824 Date abstract record published 16/07/2014 |
